

## Preparation of 6-Deoxy-6,6,6-trifluoro-D-mannose and D-Allose from Enzymatically Resolved 2-Butenolides

Takashi Yamazaki,\* Kenji Mizutani, and Tomoya Kitazume\*

Department of Bioengineering, Tokyo Institute of Technology, Nagatsuta, Midori-ku, Yokohama 227, Japan

(Received 18 January 1993)


**Abstract:** Both 6-deoxy-6,6,6-trifluoro-D-mannose and D-allose, possessing a diastereomeric relationship, were conveniently prepared from trifluorinated 2-butenolides, which was prepared via the enzymatic resolution with high efficiency.

6-Deoxy sugars are recognized as one of the most important class of materials because a various type of naturally occurring antibiotics contain such sugars, which also play a significant role on their biological activities or stabilities.<sup>1</sup> On the other hand, in connection with the fact that introduction of fluorine(s) is the widely accepted strategy for the modification of biological activities,<sup>2</sup> many kinds of fluorine-containing sugars have been reported thus far, while most of them have been the ones possessing only one or two fluorines in their framework.<sup>3</sup> This is mainly because such mono- or difluorosugars are relatively easy to be obtained through the well developed fluorination methodology by employing such a reagent as DAST<sup>4</sup> (Et<sub>2</sub>NSF<sub>3</sub>) for the transformation of a carbonyl group (ketones or aldehydes) to difluoromethylene or difluoromethyl groups, respectively, or alkaline metal fluorides<sup>5</sup> for the preparation of monofluorinated compounds via, for example, the corresponding tosylates in a high degree of retention of stereochemistry. However, the corresponding trifluoromethyl analogs have been rare in the literature,<sup>6</sup> which might stem from the fact that there are no convenient method for their construction in stereo- as well as chemoselective manners. Our basic strategy to prepare compounds with this group is the employment of the appropriately functionalized chiral building blocks,<sup>7</sup> and here, during our continuing study, the authors would like to describe our result for the preparation of 6-deoxy-6,6,6-trifluoro-D-mannose and D-allose from the same starting material, trifluorinated 2-butenolide *anti*-3 obtained from the corresponding furanol 2 by highly efficient enzymatic resolution.<sup>8</sup>

The key intermediate in the present study, 2-butenolide *anti*-3<sup>8</sup> was prepared as shown in Scheme 1. The asymmetric transformation of *rac*-1 by lapse PS (Amano Pharmaceutical Co., Japan) showed its *E* value of 189, suggesting the very effective optical resolution. Thus, at 50% conversion, 50% (98% ee) of (*S*)-2 and 48% (94% ee) of (*R*)-1 were obtained after silica gel chromatography. The former was silylated as usual (93% yield) and was further oxidized by the modified Kuwajima-Urabe procedure<sup>9</sup> to furnish the desired trifluoromethylated 2-butenolide 3 as a 1:1 diastereomer mixture. For the purpose of obtaining one of the either isomer selectively, this mixture (*syn*- and *anti*-3) was subjected under the basic conditions (treated with LDA at -78 °C, followed by quenching the reaction mixture by acetic acid) to be successfully epimerized at their  $\gamma$ -position and 84% of *anti*-selectivity was attained (89% yield). Another important material, *anti*-4, was also produced by oxidation with potassium permanganate in the presence of a catalytic amount of 18-crown-6<sup>10</sup> with excellent diastereoselectivity<sup>11</sup> (42% yield with recovery of 33% of *anti*-3). This would be the reflection of the effective shielding of the butenolide ring by such a sterically demanding substituent as 1-*t*-butyldimethylsiloxy-2,2,2-trifluoroethyl group.


The access to the CF<sub>3</sub> analog of D-allose from *anti*-4 was realized by the ready three-step process. Thus,

## Scheme 1



protection of diol function of *anti-4* as its acetonide followed by the DIBALH reduction furnished *anti-5*, which was then subjected to the previously reported base-promoted isomerization conditions (Scheme 2).<sup>12</sup> The driving force of this process is assumed to be the difference of the alkoxide stability between **Int-B** and **Int-C**, the latter being more favorable due to the effect of the strongly electron withdrawing CF<sub>3</sub> group and eventually recycled to be converted to **Int-D**. The sequence shown in Scheme 1 transformed *anti-5* into a mixture of the desired product *anti-6*,<sup>13</sup> starting material *anti-5*, and another type of TBS migration product *anti-7* in 35, 46, and 17% yield, respectively. The lower yield might be explained by the rigidity of the molecule due to the fused

## Scheme 2




acetamide five-membered ring prohibiting the smooth ring opening (see, for example, the step from **Int-A** to **Int-B** in Scheme 2), which is in sharp contrast to the previous cases observed for the preparation of D-amictose and D-rhodinose with a CF<sub>3</sub> moiety. In spite of the lower conversion, since each product was easily separated by silica gel column chromatography, the recovered **anti-5** could be again subjected to the same reaction conditions.

On the other hand, the preparation of 6-deoxy-6,6,6-trifluoro-D-mannose requires dihydroxylation from the opposite olefinic face. From the mechanistic consideration, this might be solved by simply changing the order of dihydroxylation and isomerization steps: thus, if the transformation of **anti-3** into **anti-8** is successful, then a bulky TBSO moiety would cover the β-face of the latter and the proximity of potassium permanganate to the less hindered α-face could realize the construction of the desired stereostructure (Scheme 3).

This hypothesis was in fact verified as depicted in Scheme 3. DIBALH reduction of **anti-3** followed by the action of KOBu<sup>t</sup> effected the isomerization to furnish **anti-8** in 63% yield along with the lactol from **anti-3**<sup>14</sup>) (33% yield). After separation and derivatization into methyl glycoside, permanganate oxidation has led to a stereochemically pure diol as our expectation (55% yield and 14% of recovery) and the product was isolated as the diacetate form (**anti-9**). Desilylation of **anti-9** afforded **anti-10** (62%) along with a mixture of unidentified materials. The fact that this mixture and **anti-10**, after separation, were acetylated to produce the same compound **anti-11**<sup>13</sup>) allowed us to speculate that the above unknown mixture was consisted from regioisomeric acetates as described in Scheme 3 (92% total yield for the deprotection-acetylation steps).

The present work describes the novel and easy pathway to access both trifluoromethylated 6-deoxy-D-mannose (D-rhamnose) and D-allose in a highly stereoselective manner via the base-promoted TBS migration as the key step. The preparation of other deoxy-6,6,6-trifluorinated sugars are in progress in our laboratory, whose results as well as the full detail of this work will be published elsewhere.

Scheme 3



- a) DIBALH, b) KOBu<sup>t</sup>, c) MeOH, H<sup>+</sup>, d) KMnO<sub>4</sub>, cat. 18-crown-6,  
e) Ac<sub>2</sub>O, pyr, f) TBAF

## References

- 1) *Bioactive Carbohydrates in Chemistry, Biochemistry, and Biology*, Kennedy, J. F.; White, C. A., Eds.; Ellis Horwood: Chichester, 1983; Chapter 12.
- 2) a) Welch, J. T.; Eswarakrishnan, S. *Fluorine in Bioorganic Chemistry*, John Wiley & Sons: New York, 1991. b) Welch, J. T. *Tetrahedron* **1987**, *43*, 3123-3197. c) Filler, R.; Kobayashi, Y. *Biomedical Aspects of Fluorine Chemistry*; Kodansha & Elsevier Biomedical: Tokyo, 1982.
- 3) For a review, see a) Tsuchiya, T. *Adv. Carbohydr. Chem. Biochem.* **1990**, *48*, 91-277. b) *Fluorinated Carbohydrates Chemical and Biochemical Aspects* (ACS symposium Series No. 374), Taylor, N. F., Ed; ACS: Washington, D. C., 1988.
- 4) Hudlicky, M. *Org. React.* **1988**, *35*, 513-637.
- 5) Sharts, C. M.; Sheppard, W. A. *Org. React.* **1974**, *21*, 125-406.
- 6) a) Bansal, R. C.; Dean, B.; Hakomori, S.; Toyokuni, T. *J. Chem. Soc., Chem. Commun.* **1991**, 796-798. b) Hanzawa, Y.; Uda, J.; Kobayashi, Y.; Ishido, Y.; Taguchi, T.; Shiro, M. *Chem. Pharm. Bull.* **1991**, *39*, 2459-2461. c) Differding, E.; Frick, W.; Lang, R. W.; Martin, P.; Schmit, C.; Veenstra, S.; Greuter, H. *Bull. Soc. Chim. Berg.* **1990**, *99*, 647-671.
- 7) a) Kitazume, T.; Yamazaki, T. In *Selective Fluorination in Organic and Bioorganic Chemistry* (ACS Symposium Series No. 456), Welch, J. T., Ed.; ACS, Washington, D. C., 1991, Chapter 12. b) Yamazaki, T.; Haga, J.; Kitazume, T. *Chem. Lett.* **1991**, 2175-2178. c) Yamazaki, T.; Okamura, N.; Kitazume, T. *Tetrahedron: Asymmetry* **1990**, *1*, 521-524.
- 8) Yamazaki, T.; Mizutani, K.; Takeda, M.; Kitazume, T. *J. Chem. Soc., Chem. Commun.* **1992**, 55-57. Some figures in this communication were incorrectly drawn. See, *J. Chem. Soc., Chem. Commun.* **1992**, 796 on their correction. The full detail will be also published elsewhere.
- 9) Kuwajima, I.; Urabe, H. *Tetrahedron Lett.*, **1981**, *22*, 5191-5194.
- 10) Mukaiyama, T.; Tabusa, F.; Suzuki, K. *Chem. Lett.* **1983**, 173-174.
- 11) Only one isomer with the depicted stereochemistry was obtained.
- 12) For the related silyl migration reactions, see the following. a) Mulzer, J.; Schöllhorn, B. *Angew. Chem. Int. Ed. Engl.* **1990**, *29*, 431-432 (with a *t*-butyldiphenylsilyl group). b) Jones, S. S.; Reese, C. B. *J. Chem. Soc. Perkin Trans. 1* **1979**, 2762-2764 (with a *t*-butyldimethylsilyl group). See also, Watanabe, Y.; Fujimoto, T.; Ozaki, S. *J. Chem. Soc., Chem. Commun.* **1992**, 681-683.
- 13) **anti-6**: mp 87.5-88.0 °C. <sup>1</sup>H NMR δ 0.08 and 0.11 (3 H each, s, Si(CH<sub>3</sub>)<sub>2</sub>), 0.88 (9 H, s, C(CH<sub>3</sub>)<sub>3</sub>), 1.33 and 1.50 (3 H each, s, C(CH<sub>3</sub>)<sub>2</sub>), 3.26 (1 H, d, *J* = 3.85 Hz, OH), 4.12 and 4.43 (1 H each, dd and m, *J* = 3.12, 6.80 Hz, CHCHCHOH), 4.16 (1 H, dq, *J* = 8.60, 7.21 Hz, CF<sub>3</sub>CH), 4.47 (1 H, dd, *J* = 2.75, 8.51 Hz, CF<sub>3</sub>CHCH), 5.02 (1 H, t, *J* = 3.45 Hz, CHOCH<sub>3</sub>). <sup>13</sup>C NMR δ -4.99 and -4.70 (s each, Si(CH<sub>3</sub>)<sub>2</sub>), 18.02 (s, C(CH<sub>3</sub>)<sub>3</sub>), 24.84 and 26.78 (s each, C(CH<sub>3</sub>)<sub>2</sub>), 25.61 (s, C(CH<sub>3</sub>)<sub>3</sub>), 64.47, 74.17, and 76.08 (s each, CHCHCHCHOCH<sub>3</sub>), 71.12 (q, *J* = 29.6 Hz, CF<sub>3</sub>CH), 93.98 (s, CHOCH<sub>3</sub>), 112.50 (s, C(CH<sub>3</sub>)<sub>2</sub>), 123.53 (q, *J* = 281.8 Hz, CF<sub>3</sub>). <sup>19</sup>F NMR δ 4.2 (d, *J* = 6.2 Hz). IR (KBr) ν 3400, 3000, 2950, 2900, 2875. HRMS calcd for C<sub>15</sub>H<sub>28</sub>F<sub>3</sub>O<sub>5</sub>Si *m/e* (M+H) 373.1658, found 373.1660. **anti-11**: R<sub>f</sub> 0.49 (AcOEt:Hex = 1:2). <sup>1</sup>H NMR δ 2.01, 2.05, and 2.17 (3 H each, s, C(O)CH<sub>3</sub>), 3.47 (3 H, s, OCH<sub>3</sub>), 4.15 (1 H, ddq, *J* = 0.59, 9.83, 6.00 Hz, CF<sub>3</sub>CH), 4.81 (1 H, d, *J* = 1.84 Hz, CHOCH<sub>3</sub>), 5.24 (1 H, dd, *J* = 1.79, 3.36 Hz, CHCHOCH<sub>3</sub>), 5.35 (1 H, dd, *J* = 3.40, 9.93 Hz, CHCHCHOCH<sub>3</sub>), 5.54 (1 H, t, *J* = 9.84 Hz, CF<sub>3</sub>CHCH). <sup>13</sup>C NMR δ 20.51, 20.63, and 20.83 (s each, C(O)CH<sub>3</sub>), 55.89 (s, OCH<sub>3</sub>), 64.04, 68.33, and 68.84 (s each, CF<sub>3</sub>CHCHCHCH), 68.33 (q, *J* = 31.3 Hz, CF<sub>3</sub>CH), 98.68 (s, CHOCH<sub>3</sub>), 123.32 (q, *J* = 280.3 Hz, CF<sub>3</sub>), 169.16, 169.82, and 170.04 (s each, C=O). <sup>19</sup>F NMR δ 5.4 (d, *J* = 6.9 Hz). IR (neat) ν 2950, 2850, 1765, 1750. HRMS calcd for C<sub>13</sub>H<sub>18</sub>F<sub>3</sub>O<sub>8</sub> *m/e* (M+H) 359.0953, found 359.0977.
- 14) The lactol from **anti-3** itself could not be recovered because of its unstable nature under the isolation conditions, giving furan shown in the right.

